XTL BIOPHARMACEUTICALS LTD
XTLB evidence brief
What we can confirm
- Market Cap:
- $6.0M
What it means
What to watch
Prepared research question
What matters most for XTLB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · XTLB
XTL Biopharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on acquiring and developing treatments for autoimmune diseases and central nervous system disorders, with no commercialized products and a history of operating losses.
Key risk: Cash runway uncertainty
Market Cap
$6.0M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
XTL Biopharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on acquiring and developing treatments for autoimmune diseases and central nervous system disorders, with no commercialized products and a history of operating losses.
- As of December 31, 2024, XTL had $371 thousand in cash and cash equivalents, down from $1,401 thousand a year earlier [sec · filed 2025-04-30].
- The company incurred a net loss of $6,969 thousand for the year ended December 31, 2025, comprising a loss from continuing operations of $759 thousand and a loss from discontinued operations of $6,210 thousand [sec · filed 2026-06-30].
- XTL acquired Psyga Bio in June 2026, adding Phase 2a clinical trials expected to start enrollment across several CNS indications, including mental health disorders and addiction treatment [sec · filed 2026-06-30].
- As of December 31, 2023, the company had an accumulated deficit of approximately $158,246 thousand [sec · filed 2024-04-30].
- XTL has had no drug product sales to date and relies on outside financing to continue operations [sec · filed 2024-04-30].
What works
- The acquisition of Psyga Bio in June 2026 provides a pipeline of Phase 2a-ready CNS programs, several of which are fully funded and expected to be conducted with leading academic institutions [sec · filed 2026-06-30].
- The company has a focused strategy to expand its IP portfolio and identify additional assets, potentially diversifying its pipeline [sec · filed 2024-04-30].
- XTL has raised net proceeds of approximately $87.4 million historically from various private placements and public offerings, indicating some access to capital markets [sec · filed 2025-04-30].
What to weigh
- XTL has incurred continuing losses since inception and depends on outside financing to sustain operations, with no assurance of future funding [sec · filed 2024-04-30].
- Cash and cash equivalents declined sharply from $1,401 thousand at December 31, 2023 to $371 thousand at December 31, 2024, reducing the cash runway [sec · filed 2025-04-30].
- The company has not yet commercialized any drug candidates and faces substantial uncertainty in obtaining regulatory approval and market acceptance in highly regulated markets [sec · filed 2024-04-30].
- Available financial data shows a net loss from continuing operations of $759 thousand in fiscal 2025, with no revenue from product sales [sec · filed 2026-06-30].
From the filings
Quoted directly from source documents.
Cash position as of December 31, 2024 was $371 thousand
“As of December 31, 2024, we had approximately $371 thousand in cash and cash equivalents”
SEC filings · April 30, 2025
Net loss of $6,969 thousand for the year ended December 31, 2025
“The Company has incurred a net loss of $6,969 thousands for the year ended December 31, 2025”
SEC filings · June 30, 2026
Acquisition of Psyga Bio in June 2026 and Phase 2a plans in multiple CNS indications
“approved Phase 2a human clinical trials, which are expected to commence patient enrollment in the near future, across multiple indications, including mental health disorders, neurological conditions, trauma-related disorders, addiction treatment and additional central nervous system indications.”
SEC filings · June 30, 2026
Accumulated deficit of approximately $158,246 thousand as of December 31, 2023
“accumulated deficit of approximately $158,246 thousand”
SEC filings · April 30, 2024
Risks & what to watch (4)›
Key risks
- Cash runway uncertainty — With only $371k cash at Dec 2024, XTL may need financing soon to fund operations [sec · filed 2025-04-30].
- No revenue or approved products — XTL has no product sales to date and depends on external financing [sec · filed 2024-04-30].
- Clinical trial risk for Psyga Bio — Phase 2a trials may not produce positive results, delaying pipeline development [sec · filed 2026-06-30].
- Regulatory and market competition — The biopharmaceutical market is highly regulated; market acceptance uncertain [sec · filed 2024-04-30].
What to watch
- Initiation or update of patient enrollment in Phase 2a CNS trials for Psyga Bio [sec · filed 2026-06-30].
- Any new financing or collaboration agreements to address low cash position [sec · filed 2025-04-30].
- Additional asset acquisitions or in-licensing deals to expand pipeline beyond Psyga Bio [sec · filed 2024-04-30].
- Future financial reports to see cash burn and net loss trends after Psyga Bio acquisition [sec · filed 2026-06-30].
Sources: SEC filings · Generated September 11, 2026 · How we verify sources →
Run XTL BIOPHARMACEUTICALS LTD through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available XTL BIOPHARMACEUTICALS LTD facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
6
Total value held
$55K
| Holder | Shares | Value |
|---|---|---|
| smartharvest portfolios, llc | 13,351 | $32K |
| rhumbline advisers | 5,987 | $14K |
| gamma investing llc | 3,388 | $8K |
| tower research capital llc (trc) | 244 | $588 |
| noked israel ltd | 49,722 | $120 |
| morgan stanley | 10 | $24 |
Short Interest
as of May 22, 2026- % of float
- 277.5%
- Days to cover
- 0.1
- Shares short
- 680,467
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
XTLB short interestFrequently asked questions
What is the AI investment thesis for XTL BIOPHARMACEUTICALS LTD?
XTL Biopharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on acquiring and developing treatments for autoimmune diseases and central nervous system disorders, with no commercialized products and a history of operating losses.
Who is the CEO of XTL BIOPHARMACEUTICALS LTD?
Mr. Noam Band is the chief executive officer of XTL BIOPHARMACEUTICALS LTD (XTLB).
Where is XTL BIOPHARMACEUTICALS LTD headquartered?
XTL BIOPHARMACEUTICALS LTD (XTLB) is headquartered in Herzliya, Israel.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.